John C. Reed - May 1, 2024 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Innovative Medicine, R&D
Signature
/s/ Raavi Deol, as attorney-in-fact for John C. Reed
Stock symbol
JNJ
Transactions as of
May 1, 2024
Transactions value $
-$1,588,177
Form type
4
Date filed
5/3/2024, 04:31 PM
Previous filing
Feb 20, 2024
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +22.3K +7272.88% $0.00 22.6K May 1, 2024 Direct F1
transaction JNJ Common Stock Tax liability -$1.59M -11K -48.69% $144.59 11.6K May 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -22.3K -29.37% $0.00 53.5K May 1, 2024 Common Stock 22.3K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Restricted Share Units.